Library

Research Protocol Library

Reference frameworks drawn from published preclinical and clinical literature. Every protocol below is summarized from peer-reviewed sources or regulatory filings — not authored by PepGuide.

Research-use only. Educational reference.

These summaries are aggregated from third-party scientific literature for laboratory and educational reference. They are not medical advice, not dosing recommendations for human use, and not endorsed by the cited authors or institutions. Compounds referenced are not approved by the FDA for the indications discussed unless explicitly noted.

Fat-Loss Research Models

Adipose tissue & metabolic regulation

Protocols frequently cited in preclinical and clinical literature for visceral adipose tissue reduction and metabolic markers. Most published frameworks pair a GH-axis or incretin compound with controlled caloric and activity variables.

AOD-9604TesamorelinGLP-1 analogsMOTS-c

Framework

Baseline (Week 0): Body composition (DEXA), fasting glucose, HbA1c, lipid panel, IGF-1.
Induction (Weeks 1–4): Lower end of cited dose ranges to assess tolerability; daily subcutaneous administration in most published designs.
Maintenance (Weeks 5–12): Mid-range dosing with periodic markers (every 4 weeks).
Washout / Reassessment: 2–4 week clearance window before reassessment of body composition and metabolic markers.

Key considerations

Tesamorelin showed −15.2% visceral adipose tissue reduction vs +5.0% placebo at 26 weeks (Falutz et al., NEJM 2007).
GLP-1 receptor agonists may transiently elevate resting heart rate and cause GI symptoms.
AOD-9604 has not shown clinically significant weight loss in published Phase II trials at standard doses.

Cited sources

Recovery & Soft-Tissue Repair

Tendon, ligament, GI mucosa

Animal-model protocols for connective tissue and gastrointestinal healing. Human clinical data remain limited; most evidence is preclinical (rat tendon, colitis, and ischemia/reperfusion models).

BPC-157TB-500 (TB4 fragment)GHK-Cu

Framework

Acute Injury (Days 0–14): Daily dosing throughout acute inflammatory phase in animal studies.
Repair (Weeks 2–6): Continued daily or twice-daily administration through proliferative phase.
Remodeling (Weeks 6–12): Tapered frequency aligned with collagen remodeling timelines.

Key considerations

BPC-157 has no published Phase III human trials; FDA has issued warnings against compounding (Sept 2023).
TB-500 / Thymosin Beta-4 is prohibited by WADA in sport.
GHK-Cu human evidence is strongest in topical dermatologic applications.

Cited sources

Cognitive Performance

Attention, neurotrophic signaling

Nootropic peptides researched primarily in Russian clinical and animal literature. Intranasal administration dominates published protocols for Semax and Selank.

SemaxSelankCerebrolysin

Framework

Loading: Multiple daily intranasal administrations over 10–14 days in cited acute-stroke and anxiolytic studies.
Maintenance: Lower frequency dosing over 4–8 weeks.

Key considerations

Semax is registered as a medication in Russia; not FDA-approved.
Most cognitive outcome measures rely on subjective scales and small sample sizes.

Cited sources

Longevity & Cellular Energy

Telomere length, NAD+ pools, sirtuin activity

Geroprotective protocols studied in animal and small human cohorts. Outcomes typically measured via telomere length, melatonin rhythm, and metabolic markers.

EpithalonNAD+MOTS-c

Framework

Cycle: 10–20 day daily-dosing cycles, repeated quarterly in published Khavinson protocols.
NAD+ infusion designs: Slow IV administration over 2–4 hours per session for tolerability.

Key considerations

Epithalon clinical data largely from a single Russian research group (Khavinson lab) — independent replication is limited.
NAD+ IV protocols frequently cause flushing, chest tightness, and nausea if infused rapidly.

Cited sources

Sleep Architecture Research

Delta-wave activity, sleep onset

Protocols examining slow-wave sleep, GH pulse alignment with sleep stages, and circadian markers. GH secretagogues are most commonly administered pre-sleep in published designs.

DSIPCJC-1295/Ipamorelin

Framework

Baseline polysomnography: 2-night PSG to characterize sleep architecture.
Intervention (4–8 weeks): Pre-sleep administration; weekly subjective sleep diaries.

Key considerations

DSIP human evidence is sparse and dated; most data are from the 1980s.
GH secretagogues can transiently elevate fasting glucose.

Cited sources

GH / IGF-1 Axis Research

Endogenous GH pulse, IGF-1 response

Protocols designed to characterize endogenous GH secretion patterns and IGF-1 response without exogenous rhGH administration.

SermorelinTesamorelinIpamorelinCJC-1295

Framework

Provocation testing: Single-dose GHRH/ghrelin agonist with serial GH sampling (q15 min × 2h).
Chronic stimulation: Nightly pre-sleep dosing over 8–12 weeks with monthly IGF-1.

Key considerations

Sustained GH-axis stimulation can elevate fasting glucose and HOMA-IR.
IGF-1 elevation has theoretical proliferative concerns — exclusion of active malignancy is standard in clinical studies.

Cited sources

Sources sourced from PubMed, NEJM, Cell Metabolism, Frontiers, and FDA public records. PepGuide does not author the underlying research and makes no claim of medical efficacy.